{"entity":{"id":"tilt-biotherapeutics","kind":"company","name":"TILT Biotherapeutics","aka":["TILT Biotherapeutics Ltd"],"tldr":"TILT Biotherapeutics is a Finnish biotech founded by Akseli Hemminki whose oncolytic adenovirus TILT-123 produces TNF-alpha and IL-2 in the tumour to help checkpoint inhibitors and TIL therapy work.","summary":"TILT Biotherapeutics develops armed oncolytic adenoviruses that replicate in cancer cells and express immune cytokines. TILT-123 (igrelimogene litadenorepvec) carries genes for tumour necrosis factor alpha and interleukin-2, and has been tested with pembrolizumab in platinum-resistant ovarian cancer, with avelumab in solid tumours and with tumour-infiltrating lymphocyte therapy in melanoma. The company has also received funding for phase 2 development in ovarian cancer.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.tiltbio.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["tilt-123"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Helsinki","country":"FI","companyType":"biotech","website":"https://www.tiltbio.com/","founded":2013,"investors":[],"funding":[]},"route":"/companies/tilt-biotherapeutics/","neighbours":{"drug":[{"id":"tilt-123","kind":"drug","name":"TILT-123","route":"/drugs/tilt-123/"}]}}